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Letter LetterAdvances in the classiﬁcation of diffuse large B cell lymphoma
(DLBCL) based on genetic aberrations and molecular expression
proﬁles have led to the recognition of a new category of high grade B
cell lymphoma, including “high grade B-cell lymphoma with
rearrangements of MYC and BCL2 and/or BCL6”, in the 2016
revised 4th edition of World Health Organization (WHO)
ClassiﬁcationofTumorsofHaematopoietic andLymphoidTissues.1
The poor results achieved with R-CHOP (Rituximab, Cyclo-
phosphamide, Doxorubicin, Vincristine and Prednisone) in
multiple studies, have prompted the use of intensive treatments,
such as Burkitt lymphoma regimens, stem-cell transplantation or
dose-adjusted EPOCH-R (DA-EPOCH-R)2–6 as ﬁrst line treat-
ments, even if no prospective comparisons are available.
Onthesebasesweperformeda“real life” retrospectivemulticenter
study with the aim of characterizing the clinical and pathological
landscape ofMYC rearranged aggressive B-cell lymphomas in Italy,
and comparing for efﬁcacy the preferred therapeutic choices.
In the years 2011 to 2017, a total of 100 patients with newly
diagnosed DLBCL (n=65) or B cell lymphoma, unclassiﬁable
(BCLU, n=35) were collected from 29 Italian centers of the
Fondazione Italiana Linfomi (FIL) Fig. S1 (Supplemental Digital
Content, http://links.lww.com/HS/A49). Pathological data were
retrieved from centrally reviewed local pathological reports.
FISH (ﬂuorescent in-situ hybridization) analysis was performed
with current standard methods.7
Treatment groups were classiﬁed as follows: 1) “intensive
regimens”: incorporating high dose methotrexate: R-CODOX-
M/IVAC [Rituximab, Cyclophosphamide, Oncovin (Vincristine),
Doxorubicin, Methotrexate alternating with Rituximab, Ifosfa-
mide, Vepesid (etoposide), Ara-C (Cytarabine)], n=23, GMALL-
R (German Multicenter Study Group for the Treatment of AdultTable 1
Patient and Tumor Characteristics.
Features MYC rearranged (n=100)
Median age, range 61, 19-85
Male sex 62 (62%)
B symptoms 37 (37%)
AAS III-IV 82 (82%)
Elevated LDH 73 (73%)
ECOG PS ≥2 36 (36%)
Extranodal sites≥2 42 (42%)
Bone marrow involvement 35 (35%)
Bulky>=6 cm 59 (59%)
CNS involvement 8 (8%)
IPI risk group
good (0) 1 (1%)
intermediate (1–2) 35 (35%)
poor (3–4–5) 64 (64%)
Histology
DLBCL NOS 65 (65%)
BCLU 35 (35%)
Cell-of-origin by Hansb
GCB 67 (67%)
non-GCB 18 (18%)
Translocations
MYC 100
BCL2 57
BCL6 29
DHL = double hit lymphomas; includes: [(MYC+/BCL2+/BCL6-), DHL-BCL2]; [(MYC+/BCL2-/BCL6+), D
SHL= single hit lymphomas (MYC+/BCL2-/BCL6-). AAS= Ann Arbor stage, BCLU= “unclassiﬁable” aggressive
speciﬁed, ECOG PS = Eastern Cooperative Oncology Group performance status, GCB = Germinal Center B-C
a 5 of them presented a concomitant rearrangement of both MYC and BCL2 and BCL6 (MYC+/BCL2+/B
b Not done in 15 patients.
2Acute Lymphoblastic Leukemia, Rituximab), n=9, R-Hyper-
CVAD/R-MA [Rituximab, Hyperfractionated Cyclophospha-
mide, Vincristine, Adriamycin (Doxorubicin), Dexamethasone
alternating with Rituximab, Methotrexate, Ara-C (Cytarabine)],
n=10; 2) “R-CHOP-like”: including also R-COMP, n=6 (R-
CHOPwith liposomal anthracycline), R-miniCHOP, n=2, R-M/
VACOP-B (Rituximab, Methotrexate/Etoposide, Doxorubicin,
Cyclophosphamide, Vincristine, Prednisone, and Bleomycin), n=
2, R-mega-CHOP, n=1; 3) “DA-EPOCH-R”: dose-Adjusted
Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Pred-
nisone and Rituximab. Patients treated with different approaches
or palliative care (“others”) were censored for survival analysis,
or analyzed separately.
The primary end-point was progression-free survival (PFS),
deﬁned as the time between lymphoma diagnosis and relapse or
progression, lack of response, or death from any cause. Survival
curves were estimated using the Kaplan-Meier product limit
method. Statistical analyses were performed using the Stata 13.0
software (Stata Corp., College Station, TX).
All 100 patients presented MYC rearrangement as for
inclusion criteria, 57 patients were double hit for BCL2 (DHL-
BCL2) and 29 were double hit for BCL6 (DHL-BCL6). The
remaining 19 MYC rearranged patients, lacking an additional
BCL2 or BCL6 translocation, were deﬁned single hit lymphomas
(SHL – MYC+/BCL2-/BCL6-). Five patients carried all the three
rearrangements, so called “triple hit lymphoma” (THL – MYC
+/BCL2+/BCL6+) and for survival analysis were considered
among DHLs.
Clinical and pathological features of the whole series are
detailed in Table 1. Eight patients had central nervous system
(CNS) involvement at diagnosis (2 parenchymal, 6 meningeal).SHL (n=19) DHL and THL (n=81)a p value
62, 19-80 61, 21-85 0.4
10 (53%) 52 (64%) 0.2
6 (32%) 31 (38%) 0.3
12 (63%) 70 (86%) 0.02
10 (53%) 63 (77%) 0.03
5 (26%) 31 (38%) 0.2
6 (32%) 36 (44%) 0.2
4 (21%) 31 (38%) 0.1
8 (42%) 51 (62%) 0.08
1 (5%) 7 (8%) 0.5
1 (5%) 0
10 (53%) 25 (31%) 0.02
8 (42%) 56 (69%)
13 (68%) 52 (64%) 0.4
6 (32%) 29 (36%)
12 (63%) 55 (67%) 0.5
4 (21%) 14 (17%)
NA
19 81
0 57 (70%)
0 29 (35%)
HL-BCL6].
B-cell lymphoma, CNS= central nervous system, DLBCL NOS= Diffuse large B cell lymphoma not otherwise
ell like, IPI = International Prognostic Index score, LDH = lactate dehydrogenase, NA = not applicable.
CL6+), the so called triple hit lymphomas (THL).
Figure 1. PFS by delivered treatment: 24 months PFS 65% (95% CI 49–68) in
patients who received intensive treatments, 46% (95% CI 29–62) in those who
received R-CHOP-like schedules (p=0.04 compared with intensive and DA-
EPOCH-R); 59% (95% CI 33–78) in patients treated with DA-EPOCH-R (p=
0.6, compared with intensive treatments) and not evaluable in patients treated
with other treatments (p=0.001).
(2019) 3:6 www.hemaspherejournal.comThe majority of patients (n=42) were treated upfront with
intensive schedules, followed by R-CHOP like (n=35) and by
DA-EPOCH-R (n=18). Five patients were treated with other
schemes (Supplementary Table S1, Supplemental Digital
Content, http://links.lww.com/HS/A49). Eighteen patients re-
ceived ASCT consolidation. Overall, 70 patients received CNS
prophylaxis: intrathecal in 24, systemic MTX in 8, and both in
38. Finally, 20 patients received radiotherapy consolidation.
Patients treated with intensive regimens presented with similar
baseline features to patients treated with R-CHOP, with
exception of more advanced IPI in intensive group (p=
0.006), and similar to DA-EPOCH-R group, with the exception
of higher ki67 values (p=0.04), and advanced stage (p=0.02).
Finally, patients presenting a BCLU histology received more
frequently intensive treatment than standard R-CHOP or DA-
EPOCH-R, p=0.001 and p=0.05, respectively, (Supplementary
Table S2, Supplemental Digital Content, http://links.lww.com/
HS/A49).
Overall response was 71%, with 58 patients achieving
complete response (CR) and 13 partial response (PR) at the
end of front-line treatment. Three patients died of treatment
related complications (infections) during induction, and one did
not receive any treatment. CR rate was 68% in SHL and 56% in
DHL (p=0.2), see Supplementary Table S2 (Supplemental
Digital Content, http://links.lww.com/HS/A49). Patients treated
with intensive schedules had a CR of 69% (29/42), which was not
statistically different from patients treated with R-CHOP (18/35,
51%, p=0.08), and similar to patients treated with DA-EPOCH-
R (11/18, 61%, p=0.4).
After a median follow up for survivors of 33 months, the 24
months PFS and OS of the overall MYC rearranged (MYC-R)
population were 54% (95% CI 44–63) and 57% (95% CI 46–
66), respectively, Fig. S2A and Fig. S2B (Supplemental Digital
Content, http://links.lww.com/HS/A49). For the 19 patients with
SHL and the 81 patients with DHL, PFS at 24 months was
77% (95% CI 51–91) and 49% (95% CI 37–59), respectively
(p=0.05), Fig. S2C (Supplemental Digital Content, http://links.
lww.com/HS/A49), and OS was 77% (95% CI 50–90) vs 52%
(95% CI 40–63), respectively (p=0.1), Fig. S2D. http://links.
lww.com/HS/A49 PFS did not vary signiﬁcantly based on the
speciﬁc double rearrangements found (ie, DHL-BCL2 vs DHL-
BCL6 vs THL), Fig. S3 (Supplemental Digital Content, http://
links.lww.com/HS/A49).
Analyzing all the MYC-R population, the 24 months PFS was
59% (95% CI 33–78) in patients treated with DA-EPOCH-R
(p=0.6, compared with intensive treatments), 46% (95%CI 29–
62) in those receiving R-CHOP-like schedules (p=0.04), and
65% (95% CI 49–68) in patients who received intensive
treatments, Fig. 1. In the same population, the 24 months OS
was 74% (95% CI 45–89) in patients treated with DA-EPOCH-
R, which was superior to patients receiving R-CHOP-like
schedules, 46% (95% CI 27–62), p=0.05. However, no
signiﬁcant OS difference was seen between DA-EPOCH-R and
intensive regimens. Moreover, restricting the analysis to the
group of elderly patients (age>65 years, n=42), no survival
advantage was observed in patients treated with DA-EPOCH-R
or intensive regimens vs R-CHOP-like. Superimposable results
were obtained selecting the 81DHLpatients only, with a PFS and
OS advantage for patients receivingDA-EPOCH-R and intensive
regimens vs R-CHOP-like (p=0.02), Fig. S4 (Supplemental
Digital Content, http://links.lww.com/HS/A49). 24 months OS
in the 81 DHL patients was 66% (95% CI 33–86) for DA-
EPOCH-R, 34% (95% CI 15–53) for R-CHOP-like (p=0.033and p=0.05 respectively), and 64% (95% CI 46–77) for
intensive treatments.
ASCT consolidation (n=18) did not give any PFS advantage in
patients achieving CR or PR at the end of induction treatment
(p=0.3 and 0.4, respectively), Fig. S5A and Fig. S5B (Supple-
mental Digital Content, http://links.lww.com/HS/A49). Actually,
patients in CR at the end of induction retained a good 24 months
PFS even without ASCT (82%–95% CI 69–90).
Moreover, despite quite aggressive CNS prophylaxis, 5/100
patients experienced a CNS relapse during observation period
(two of them presenting a CNS involvement already at
diagnosis). Finally, the outcome after relapse was very poor,
accounting for a 24 months OS of 13% (95% CI 4–24), Fig.
S6 (Supplemental Digital Content, http://links.lww.com/HS/
A49).
In the overall MYC-R population, B-symptoms (p=0.05),
ECOG performance score (PS)>2 (p=0.003), bone marrow
inﬁltration (p=0.005), elevated LDH levels (p=0.03) and poor
risk IPIaa (p=0.05), predicted worse PFS (Supplementary
Table S3, Supplemental Digital Content, http://links.lww.com/
HS/A49). Restricting analysis for DHL population, only ECOG
PS>2 (p=0.01) and bone marrow inﬁltration (p=0.05)
retained their prognostic impact. Finally, after Cox propor-
tional hazard multivariate analysis, only a poor ECOG (> 2)
remained predictive of poor PFS, p=0.009 (95% CI 1.21–
3.86), HR 2.16.
Overall, the main results of this study can be summarized as
follows:1) “High-grade B-cell lymphoma with MYC and BCL2/BCL6
rearrangements” show an overall worse prognosis than
“single-hit” MYC-R patients in terms of PFS;
frontline intensive chemotherapy and DA-EPOCH-R are2)
associated with a signiﬁcant survival beneﬁt if compared
with R-CHOP-like treatments;
restricting the analysis to the group of elderly patients, the3)
advantage for intensive regimens was no longer observed,
suggesting that younger patients might beneﬁt the most from
these schedules;
survival is not signiﬁcantly impacted by ASCT consolidation,4)
regardless of the clinical response observed;
Letter Letter5) survival after progression in “high-grade B-cell lymphoma
with MYC and BCL2/BCL6 rearrangements” is particularly
dismal, suggesting that salvage therapies are ineffective in this
setting.
Therefore, with the limits of a retrospective series, we reported
a large, National, homogeneous population, where the distribu-
tion of the baseline characteristics and the clinical results are very
similar to those of previously published unselected cohorts2,8,9 As
regards CNS relapse, its cumulative incidence was inferior to that
of the MDACC retrospective cohort8 (5% at 2 years vs 13% at 3
years). Even if the numbers are too small to drive sound
correlations between the received prophylaxis (intrathecal vs
systemic) and the characteristics of CNS relapse (meningeal vs
parenchimal), this difference might be due to a more aggressive
upfront CNS prophylaxis in our series. Finally, as screening of all
DLBCL and BCLU cases for MYC rearrangement was not the
routine practice of all participating centers, we cannot exclude the
possibility that selection bias inﬂuenced the decision to test
speciﬁc cases.
In conclusion, the results of our study conﬁrm that R-CHOP is
not an appropriate therapeutic choice for “high-grade B-cell
lymphoma with MYC and BCL2/BCL6 rearrangements”, and
that intensive regimens or DA-EPOCH-R should be preferred,
especially for younger patients. Nevertheless, the current
diagnostic work-up of aggressive B cell lymphomas is controver-
sial, and the screening strategy to drive FISH testing is not clearly
shared.10–12. Moreover, the complex biological landscape of
DLBCL probably cannot be simply resumed by classical FISH or
cell of origin analysis: actually, new biological insights, including
high-throughput mutational13,14 and microenvironmental stud-
ies,15 are needed for a better classiﬁcation and a more effective
testing of front line targeted agents.Acknowledgements
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